Profile data is unavailable for this security.
About the company
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.
- Revenue in USD (TTM)58.75m
- Net income in USD-9.06m
- Incorporated2000
- Employees339.00
- LocationMacroGenics Inc9704 Medical Center DriveROCKVILLE 20850United StatesUSA
- Phone+1 (301) 251-5172
- Fax+1 (301) 251-5321
- Websitehttps://www.macrogenics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SAGE Therapeutics Inc | 91.06m | -503.14m | 816.25m | 487.00 | -- | 1.16 | -- | 8.96 | -8.40 | -8.40 | 1.52 | 11.73 | 0.0916 | -- | 6.26 | 186,989.70 | -50.61 | -21.88 | -54.64 | -23.30 | 96.49 | 99.63 | -552.52 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
| Cullinan Therapeutics Inc | 0.00 | -153.16m | 829.01m | 85.00 | -- | 1.82 | -- | -- | -3.70 | -3.70 | 0.00 | 10.58 | 0.00 | -- | -- | 0.00 | -29.68 | -12.37 | -31.19 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
| USANA Health Sciences, Inc. | 921.01m | 63.79m | 830.04m | 1.80k | 13.08 | 1.66 | 10.85 | 0.9012 | 3.30 | 3.30 | 47.61 | 25.99 | 1.50 | 2.75 | -- | 511,672.20 | 10.38 | 16.23 | 13.20 | 21.75 | 80.82 | 81.42 | 6.93 | 8.96 | 3.00 | -- | 0.0016 | 0.00 | -7.77 | -4.98 | -8.02 | -12.76 | 4.86 | -- |
| OPKO Health Inc | 863.49m | -188.86m | 850.33m | 3.93k | -- | 0.6791 | -- | 0.9848 | -0.2513 | -0.2513 | 1.15 | 1.80 | 0.4133 | 7.80 | 6.89 | 219,718.60 | -9.03 | -7.14 | -10.03 | -8.14 | 36.84 | 34.42 | -21.86 | -13.83 | 1.22 | -15.24 | 0.1574 | -- | -14.01 | -2.70 | 42.49 | -- | -10.19 | -- |
| Immunome Inc | 14.02m | -106.81m | 851.24m | 55.00 | -- | 5.14 | -- | 60.72 | -3.33 | -3.33 | 0.7064 | 2.77 | 0.1625 | -- | -- | 254,872.70 | -123.77 | -94.54 | -148.94 | -112.66 | -- | -- | -761.92 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
| SS Innovations International Inc | 5.88m | -20.94m | 851.91m | 239.00 | -- | 59.58 | -- | 144.89 | -0.1293 | -0.1293 | 0.04 | 0.0838 | 0.3939 | -- | 2.53 | 24,601.30 | -140.31 | -161.38 | -253.40 | -449.76 | 12.13 | -79.79 | -356.17 | -495.77 | 1.30 | -52.51 | 0.2963 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
| ALX Oncology Holdings Inc | 0.00 | -160.81m | 851.92m | 72.00 | -- | 4.44 | -- | -- | -3.74 | -3.74 | 0.00 | 3.80 | 0.00 | -- | -- | 0.00 | -58.58 | -34.34 | -66.35 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0592 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| Bicycle Therapeutics PLC (ADR) | 26.98m | -180.66m | 855.02m | 284.00 | -- | 2.58 | -- | 31.70 | -5.13 | -5.13 | 0.7585 | 8.74 | 0.0536 | -- | 26.38 | 94,985.91 | -35.92 | -29.45 | -40.92 | -32.98 | -- | -- | -669.72 | -571.36 | -- | -- | 0.0764 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
| BioCryst Pharmaceuticals Inc | 331.41m | -226.54m | 857.58m | 536.00 | -- | -- | -- | 2.59 | -1.18 | -1.18 | 1.72 | -2.21 | 0.6212 | 0.1658 | 6.16 | 618,306.00 | -42.46 | -47.95 | -55.84 | -64.89 | 98.59 | 97.06 | -68.36 | -114.94 | 3.12 | -1.11 | 2.19 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
| Praxis Precision Medicines Inc | 2.45m | -123.28m | 875.53m | 82.00 | -- | 6.67 | -- | 357.80 | -23.64 | -23.64 | 0.3719 | 7.92 | 0.0241 | -- | -- | 29,841.46 | -121.41 | -74.04 | -161.17 | -85.12 | -- | -- | -5,037.88 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
| MacroGenics Inc | 58.75m | -9.06m | 898.99m | 339.00 | -- | 5.84 | 1,534.12 | 15.30 | -0.1525 | -0.1525 | 0.9462 | 2.46 | 0.203 | 6.15 | 1.76 | 173,300.90 | -3.13 | -37.76 | -3.82 | -45.53 | 86.00 | -- | -15.42 | -133.96 | 4.46 | -117.57 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
| Cassava Sciences Inc | 0.00 | -97.22m | 939.73m | 29.00 | -- | 6.68 | -- | -- | -2.32 | -2.32 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -50.31 | -30.74 | -53.23 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Liquidia Corp | 17.49m | -78.50m | 940.46m | 136.00 | -- | 17.95 | -- | 53.78 | -1.21 | -1.21 | 0.2691 | 0.6891 | 0.1413 | -- | 3.85 | 128,588.20 | -63.43 | -55.02 | -71.31 | -62.69 | 83.49 | 82.18 | -448.89 | -474.59 | -- | -26.14 | 0.4942 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
| Innoviva Inc | 310.46m | 179.72m | 947.78m | 112.00 | 6.68 | 1.41 | 4.40 | 3.05 | 2.24 | 2.24 | 3.96 | 10.66 | 0.2509 | 0.8825 | 4.19 | 2,771,991.00 | 14.52 | 26.24 | 15.62 | 28.53 | 86.27 | -- | 57.89 | 76.84 | 7.96 | -- | 0.398 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Arcutis Biotherapeutics Inc | 59.61m | -262.14m | 987.38m | 296.00 | -- | 9.38 | -- | 16.57 | -3.90 | -3.90 | 0.8602 | 0.9161 | 0.1508 | 0.483 | 3.48 | 201,371.60 | -66.31 | -65.64 | -74.24 | -71.72 | 91.63 | -- | -439.79 | -1,513.03 | 6.80 | -8.11 | 0.6947 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
Data as of Apr 26 2024. Currency figures normalised to MacroGenics Inc's reporting currency: US Dollar USD
63.18%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Bellevue Asset Management AGas of 31 Dec 2023 | 9.95m | 15.94% |
| T. Rowe Price Investment Management, Inc.as of 31 Dec 2023 | 5.64m | 9.03% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 4.94m | 7.91% |
| Armistice Capital LLCas of 31 Dec 2023 | 4.57m | 7.32% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 4.24m | 6.78% |
| RA Capital Management LPas of 31 Dec 2023 | 4.05m | 6.49% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.17m | 3.48% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.40m | 2.25% |
| SilverArc Capital Management LLCas of 31 Dec 2023 | 1.26m | 2.02% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 1.21m | 1.95% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
